Skip to main content


Figure 2 | Arthritis Research & Therapy

Figure 2

From: The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

Figure 2

Impact of different IL-1 blockers on health-related quality of life in patients with cryopyrin associated periodic syndromes (CAPS) evaluated by the Child Health Questionnaire (CHQ-PF 50). Squared boxes represent the mean values obtained from the patients before any treatment with IL-1 blockers (see also [11]). Triangles and circle boxes represent the mean values at the last follow-up with anakinra and canakinumab treatment, respectively. *P < 0.05 (Wilcoxon pairs test). PhS: physical summary score. PsS: psychosocial summary score.

Back to article page